Cotadutide Acetate (MEDI0382) – Purity 98.88% | GMP Factory

描述

Cotadutide acetate (MEDI0382) is a synthetic peptide designed to simultaneously activate GLP-1 and glucagon receptors. With EC?? values of approximately 6.9 pM for GLP-1R and 10.2 pM for GCGR, this dual action effectively promotes weight loss, improves glucose regulation, and reduces fibrotic tissue formation. Its multi-receptor activity makes it an excellent candidate for studying treatment strategies in obesity, type 2 diabetes, and metabolic liver disease.

Manufactured under GMP protocols with 98.88% purity, Cotadutide acetate offers high-quality, reproducible results for advanced metabolic research.

Product Specifications

Mechanism of Action & Research Applications

Cotadutide acetate targets both GLP-1 and glucagon receptors, offering combined metabolic benefits:

• GLP-1R activation: Enhances insulin release, suppresses appetite, and slows gastric emptying.

• GCGR activation: Increases energy expenditure, reduces fibrosis, and promotes lipid mobilization.

Because of this dual action, Cotadutide is especially valuable in research models focusing on:

• Weight-loss strategies

• Glucose homeostasis and insulin sensitivity

• Metabolic liver disease and tissue fibrosis

• Combination metabolic hormone therapies in obesity and diabetes

Side Effects (For Research Context Only)

In experimental models, Cotadutide acetate may induce:

• Transient gastrointestinal effects such as delayed gastric motility

• Mild, temporary increases in blood pressure or heart rate due to glucagon receptor activation

• Potential mild hypoglycemia under fasting or static glucose-level protocols

• Modulation of lipid profiles and hepatic fat accumulation in metabolic assays

These effects are context-dependent and monitored within controlled study designs to inform therapeutic potential.

Disclaimer

Cotadutide Acetate is strictly for laboratory research use only. It is not approved for clinical, human, or veterinary applications.